Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript

Core Viewpoint - Regeneron is conducting a conference call to discuss its Lynozyfic development program, indicating a focus on advancing its product pipeline and engaging with investors [1] Group 1 - The conference call is hosted by Shannon, the operator, who notes that the call is being recorded [1] - Ryan Crowe, Senior Vice President of Investor Relations, is introduced as the speaker for the call [1]